These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20849302)

  • 21. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities.
    Sullivan PS; Buskin SE; Turner JH; Cheingsong R; Saekhou A; Kalish ML; Jones JL; Respess R; Kovacs A; Heneine W
    Int J STD AIDS; 2002 Aug; 13(8):554-8. PubMed ID: 12194739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals.
    Torti C; Bono L; Gargiulo F; Uccelli MC; Quiros-Roldan E; Patroni A; Paraninfo G; Tirelli V; Manca N; De Francesco MA; Perandin F; Carosi G
    Clin Microbiol Infect; 2004 Sep; 10(9):826-30. PubMed ID: 15355414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naïve and treated pediatric patients.
    Bure D; Makhdoomi MA; Lodha R; Prakash SS; Kumar R; Parray HA; Singh R; Kabra SK; Luthra K
    Viruses; 2015 Feb; 7(2):590-603. PubMed ID: 25674767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of the prevalence of HIV resistant strains to antiretroviral drug in Privolzhsky Federal District].
    Zaĭtseva NN; Parfenova OV; Efimov EI
    Vopr Virusol; 2013; 58(6):39-41. PubMed ID: 24772646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
    Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 transmitted drug resistance and genetic diversity among patients from Piauí State, Northeast Brazil.
    Moura ME; da Guarda Reis MN; Lima YA; Eulálio KD; Cardoso LP; Stefani MM
    J Med Virol; 2015 May; 87(5):798-806. PubMed ID: 25649362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi.
    Petch LA; Hoffman IF; Jere CS; Kazembe PN; Martinson FE; Chilongozi D; Fiscus SA; Cohen MS
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):799-805. PubMed ID: 16218804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs.
    Fleury H; Recordon-Pinson P; Caumont A; Faure M; Roques P; Plantier JC; Couturier E; Dormont D; Masquelier B; Simon F;
    AIDS Res Hum Retroviruses; 2003 Jan; 19(1):41-7. PubMed ID: 12596719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic resistance of antiretroviral drugs among drug-naive HIV type 1 patients with the background of long-term access-easy zidovudine therapy.
    Park SW; Kim HB; Choi YJ; Kim NJ; Oh MD; Choe KW
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):1039-43. PubMed ID: 14686324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa.
    Jacobs GB; Laten A; van Rensburg EJ; Bodem J; Weissbrich B; Rethwilm A; Preiser W; Engelbrecht S
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):1009-12. PubMed ID: 18593350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
    Charpentier C; Bellecave P; Cisse M; Mamadou S; Diakite M; Peytavin G; Tchiombiano S; Teisseire P; Pizarro L; Storto A; Brun-Vézinet F; Katlama C; Calvez V; Marcelin AG; Masquelier B; Descamps D
    Antivir Ther; 2011; 16(3):429-33. PubMed ID: 21555827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.
    Lihana RW; Khamadi SA; Lubano K; Lwembe R; Kiptoo MK; Lagat N; Kinyua JG; Okoth FA; Songok EM; Makokha EP; Ichimura H
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1211-7. PubMed ID: 19954302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile.
    Ríos M; Delgado E; Pérez-Alvarez L; Fernández J; Gálvez P; de Parga EV; Yung V; Thomson MM; Nájera R
    J Med Virol; 2007 Jun; 79(6):647-56. PubMed ID: 17457921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 drug resistant mutations in chronically infected treatment naive individuals in the pre-ARV era in Nigeria.
    Odaibo GN; Ola SO; Landerz M; Dietrich U; Olaleye DO
    Afr J Med Med Sci; 2012 Dec; 41 Suppl():61-3. PubMed ID: 23678638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.
    de Medeiros RM; Junqueira DM; Matte MC; Barcellos NT; Chies JA; Matos Almeida SE
    J Med Virol; 2011 Oct; 83(10):1682-8. PubMed ID: 21837783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.